Characteristics and Outcomes | Case series | |||||
---|---|---|---|---|---|---|
CASE 1 | CASE 2 | CASE 3 | CASE 4 | CASE 5 | CASE 6 | |
Mothers | ||||||
Maternal age, years | 27 | 26 | 30 | 34 | 35 | 28 |
Gravida/Parity | 1/1 | 1/1 | 1/1 | 5/2 | 3/3 | 1/1 |
Antiviral therapy | No | Yesa | No | No | No | No |
HBeAg status | Positive | Positive | Negative | Negative | Negative | Negative |
Baseline HBV DNA levels, log10 IU/ml | 7.48 | 4.52 | Undetected | Undetected | 2.51 | 2.52 |
Mode of delivery | Vaginal delivery | Vaginal delivery | Vaginal delivery | Caesarean section | Vaginal delivery | Vaginal delivery |
Gestational weeks at delivery | 39+ 5 | 41 | 39+ 4 | 39+ 2 | 32+ 1 | 38+ 3 |
Obstetric complications | No | No | No | No | Preterm birth | No |
FBS Technique | ||||||
Gestational weeks | 26+ 2 | 32+ 4 | 31+ 3 | 32+ 4 | 29+ 2 | 25+ 3 |
Indications | Ventricular septal defect | Ventriculomegaly | Suboccipital cystic mass | Fetal growth restriction | Hydronephrosis | Ventricular septal defect |
Transplacental penetration | Yes | No | No | No | No | No |
Post-procedure bleeding (from placenta or uterine wall) | Yes | No | No | No | No | No |
Post-procedure streaming (from punctured umbilical cord) | Yes | Yes | Yes | Yes | Yes | Yes |
Infants | ||||||
Sex | Male | Male | Male | Male | Female | Female |
Birthweight, gram | 3100 | 2950 | 3200 | 2600 | 1900 | 3400 |
HBsAg status at birth | Positive | Negative | Negative | Negative | Negative | Negative |
Timing of Follow-up, months | 12 | 12 | 29 | 32 | 12 | 38 |
HBsAg status at the end of follow-up | Positive | Negative | Negative | Negative | Negative | Negative |
Anti-HBs status at the end of follow-up | Negative | Positive | Positive | Positive | Positive | Positive |